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Karyotypic abnormalities of chromosome 6, especially 6q, repre-
sent a frequent cytogenetic alteration associated with a variety of
human malignancies (Teyssier and Ferre, 1992). In a compilation
of the results from 3185 neoplasms, Mertens et al reported that
cytogenetically identified deletions of a part of the long arm of
chromosome 6 were commonly observed in 11 types of solid
tumours, including malignant melanomas and glioblastomas
(Mertens et al, 1997). Other cytogenetic studies have shown
involvement of 6q in both low-grade and high-grade astrocytic
tumours (Jenkins et al, 1989; Thiel et al, 1992). Comparative
genomic hybridization (CGH) analysis and restriction fragment
length polymorphism (RFLP) studies have confirmed a high inci-
dence of deletion of 6q in astrocytic gliomas (Fults et al, 1990;
Ransom et al, 1992; Liang et al, 1994; Mohapatra et al, 1995;
Weber et al, 1996), while allelic loss on 6p is limited (Saitoh et al,
1998). Further evidence for the presence of tumour suppressor
gene(s) on chromosome 6 comes from microcell-mediated chromo-
some transfer into melanoma cell lines that resulted in suppression
of metastatic ability and even tumorigenicity (Trent et al, 1990;
Welch et al, 1994). Despite all these data no tumour suppressor
gene(s) have definitely been identified on chromosome 6.
Deletion mapping of chromosomes 9, 10, 13, and 17 were
instrumental in the identification of tumour suppressor genes
targeted in the oncogenesis and progression of the adult astrocytic
gliomas (Fults et al, 1990; Ransom et al, 1992; Ichimura et al,
1994). Definition of commonly lost regions and the identification
of homozygous deletions led to the following genes being impli-
cated in glial oncogenesis or progression: CDKN2A/B at 9p21
(Schmidt et al, 1994, 1997), PTEN/MMAC1 at 10q23 (Li et al,
1997), RB1 at 13q14 (Henson et al, 1994; Ichimura et al, 1996)
and TP53 at 17p13 (Rasheed et al, 1994).
We report here on an attempt to minimize the region on chro-
mosome 6 that is likely to contain a tumour suppressor gene impli-
cated in adult astrocytic gliomas. The World Health Organization
(WHO) classifies these tumours into astrocytomas malignancy
grade II, anaplastic astrocytomas malignancy grade III and
glioblastomas malignancy grade IV (Kleihues et al, 1993).
Progression from less to more malignant forms of these tumours
has been well documented – but all may also arise de novo
(Russell and Rubinstein, 1989). A series of 159 adult astrocytic
gliomas of all three malignancy grades have been deletion mapped
by studying 31 loci. A number of commonly deleted regions on the
long arm of chromosome 6 have been identified and these dele-
tions have been shown to occur most frequently in the grade III
and IV tumours, indicating a role in progression.
MATERIALS AND METHODS
Patient material
Fresh surgical specimens from tumour tissues collected at the
Karolinska Hospital, Stockholm, and the Sahlgrenska Hospital,
Gothenburg, were stored at –135°C for up to 5 years before DNA
extraction. Preoperative blood samples from the patients were also
collected and stored at –20°C. A portion of each tumour piece
frozen was examined histopathologically to estimate the propor-
tion of tumour cells. Pieces containing a high percentage of
tumour cells, generally more than 90% and a minimum of 70%,
were submitted for analysis. A total of 159 human astrocytic
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39 anaplastic astrocytomas (AA, 13 recurrent tumours), 14 astro-
cytomas grade II (A) were analysed. The study has been approved
by the ethical committee of the Karolinska Institute (No. 91:16).
DNA extraction
DNA extraction was performed as described previously (Ichimura
et al, 1996). Briefly, tumour pieces were homogenized in 4 M
guanidine thiocyanate solution, overlaid on 5.7 M caesium chlo-
ride buffer and centrifuged at 170 000 g for 16 h at 23°C. DNA
was then extracted from the CsCl phase. Blood samples were
treated with 5% Triton X-100 in 0.32 M sucrose to isolate nuclear
pellets. The nuclear pellets were digested using proteinase K and
the DNA was extracted by phenol–chloroform extraction.
Microsatellite analysis
The following 31 microsatellite markers which span the entire
chromosome 6 were used (Figure 1): D6S344, D6S1574, D6S309,
D6S470, D6S1721, D6S429, D6S260, D6S276 and D6S282 on 6p,
D6S430, D6S460, D6S275, D6S434, D6S1563, D6S1657,
D6S407, D6S1572, D6S975, D6S292, D6S311, D6S441,
D6S1577, D6S415, D6S437, D6S1581, D6S305, D6S1599,
D6S1719, D6S297, D6S1590 and D6S281 on 6q. All microsatel-
lite markers were purchased from Research Genetics (Huntsville,
AL, USA). The data were analysed on the basis of the order of
microsatellite markers on the chromosome as reported by the
CEPH/Genethon Chromosome 6 linkage map (Figure 1, GDB:
1104325) (Dib et al, 1996). The average distance between each
marker was 5.2 cM (the minimum was 1.1 cM and the maximum
was 21.5 cM, Figure 1). Paired tumour and blood DNA samples at
a concentration of 10 ng ml–1 were aligned in 96-well plates and
polymerase chain reaction (PCR) mixtures were prepared using a
Biomek 2000 (Beckman Instruments, Fullerton, CA, USA). The
optimal annealing temperature was determined for each primer
pair using a RoboCycler Gradient 96 (Stratagene, La Jolla, CA,
USA). PCR was performed for each template DNA (40 ng) in 8 ml
reaction volumes with 10 mM Tris pH 8.3, 50 mM potassium chlo-
ride, 12.5 mM of each dATP, dCTP, dGTP and dTTP, 1.5 mM
of magnesium chloride, 0.5 mM of each primer, 0.7–2 mCi of 
[a-33P]dATP and 0.2 U of TaqGold polymerase (Perkin-Elmer,
Norwalk, CT, USA). After initial denaturation at 94°C for 15 min,
18–22 cycles of amplification were performed with denaturation at
94°C for 1 min, annealing at the optimized temperature for 1 min,
and extension at 72°C for 1 min, followed by a final extension 
for 10 min on a GeneAmp PCR System 9600 (Perkin-Elmer). The
PCR products were electrophoresed on a 5 or 6% non-denaturing
polyacrylamide gel, depending on the fragment size, using
GeneLoader II (Bio-Rad, Hercules, CA, USA). Gels were
transferred to Whatman 3 MM papers, dried and exposed to
Storage phosphor screens. The screens were then scanned using 
a PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA)
and the images were analysed by ImageQuant version 3.3 software
(Molecular Dynamics).
RESULTS
Assessment of the allelic status in tumours was carried out in the
following manner. Using ImageQuant software a densitometric
profile was drawn across the bands for blood and for tumour. A
decrease in signal intensity from one of the alleles in tumour
compared to blood was judged as allelic imbalance. In most cases
with allelic imbalance, one allele had almost completely disap-
peared in tumour and this was interpreted as complete allelic loss
(Figure 2: GB55 at D6S415, GB56 at D6S1719 and GB140 at
D6S1577). The residual signals from some tumours were
decreased by 30 to 70% of the corresponding normal band in
blood (visual assessment of densitometric profiles) (Figure 2: GB8
at  D6S1657, GB145 at D6S311, GB86 at D6S311, AA65 at
D6S1719 and AA90 at D6S305). In these cases the high residual
signal was not attributed to normal cells since the cell content in
the tumour pieces was 70% or more (Figure 1). In addition the
same tumour could show almost complete allelic loss at some loci
and partial allelic loss at others (D6S434 and D6S275 in GB47,
Figure 3). Such observations were interpreted as the existence of
distinct tumour subpopulations with and without deletion at a
particular locus within the tumour tissue (Ichimura et al, 1998).
This phenomenon was designated as partial allelic loss.
Fifty-six of the 159 tumours (35%) demonstrated allelic loss at one
or more loci on chromosome 6 (Tables 1 and 2). These included
39/106 (37%) glioblastomas, 15/39 (38%) anaplastic astrocytomas
and 2/14 (14%) astrocytomas. Ten tumours (eight glioblastomas and
two anaplastic astrocytomas) showed allelic loss at all informative
loci, consistent with monosomy of chromosome 6. Forty-six tumours
had allelic loss at one or more informative loci with retention of both
alleles at a minimum of one locus (partial deletion of chromosome
6). Among these, three tumours (GB12, GB44 and AA7, Figure 1)
had allelic loss only on 6p, while the majority, 34 tumours (24
glioblastomas, nine anaplastic astrocytomas and one astrocytoma)
had losses only on 6q. Nine tumours (five glioblastomas, three
anaplastic astrocytomas and one astrocytoma) had losses of alleles
on both 6p and 6q. In total only 22/159 (14%) tumours had allelic
loss at one or more loci on 6p. Allelic loss at one or more 6q loci was
demonstrated in a total of 53 tumours (33%; 37 glioblastomas, 14
anaplastic astrocytomas and two astrocytomas) (Table 1). The inci-
dence of allelic loss was almost identical among glioblastomas and
anaplastic astrocytomas but considerably lower in astrocytomas.
To determine commonly deleted regions (CDRs), cases
showing allelic loss were compared (Figure 1). When a locus
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Table 1 Frequencies and extent of chromosome 6 allelic loss in astrocytic gliomas
No. of Any Only 6p Only 6q 6p and 6q Monosomy
tumours deletions deletions deletions deletions
GB 106 39 (37%) 2 (2%) 24 (23%) 5 (5%) 8 (8%)
AA 39 15 (38%) 1 (3%) 9 (23%) 3 (8%) 2 (5%)
A 14 2 (14%) 0 1 (7%) 1 (7%) 0
Total 159 56 (35%) 3 (2%) 34 (2%) 9 (6%) 10 (6%)
GB, glioblastomas; AA, anaplastic astrocytomas; A, astrocytomas grade II.Chromosome 6 deletions in astrocytic tumours 545
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Figure 1 Deletion mapping of chromosome 6 in human astrocytic tumours showing tumours with loss of alleles. Distances (cM) between each marker
according to CEPH/Genethon Chromosome 6 Linkage map (GDB: 1104325) are shown on the top of the panel. The position of the centromere is indicated by
an arrow. Cases of monosomy are not shown with the exception of GB226 and GB99. These two cases showed partial loss of alleles at some 6q loci and
complete loss at others, indicating subpopulations of tumour cells. Commonly deleted regions (CDRs) are shown as bars above markers (see Results). Cases
that define CDRs are marked with the corresponding CDR number on the leftbetween a deleted and a non-deleted locus was non-informative,
the deletion was considered to extend over the non-informative
locus (e.g. D6S441 and D6S415 in GB140, Figure 1). When an
overlapping region of deletion was defined, it was assumed that
the cases share a single critical region. The smallest overlapping
deleted region was then defined as the commonly deleted region.
Deletions which encompassed more than one minimal overlapping
region were not used to define CDRs. According to this principle,
five non-overlapping commonly deleted regions (CDR1–5) were
defined on 6q. Their sizes ranged from 7 to 19.2 cM (Figure 1).
The most centromeric region of deletion is located between
D6S460 and  D6S434 (CDR1). This 19.2 cM region is defined by an
interstitial deletion at D6S275 with retention of both alleles at
D6S460 and  D6S434 in AA100 (Figure 1). The two bands at D6S275
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Table 2 Patterns of allelic loss of chromosome 6 in astrocytic gliomas
Only 6p Only 6q 6p and 6q Monosomy Total
deletions deletions deletions
GB C 1 13 0 3 17
P1 1 1 5 5 2 2
AA C 1 2 0 1 4
P0 7 3 1 1 1
AC 0 0 0 0 0
P0 1 1 0 2
GB, glioblastomas; AA, anaplastic astrocytomas; A, astrocytomas grade II;
C, complete allelic loss only; P, partial allelic loss, including combination of
complete and partial allelic loss.
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Figure 2 Examples of microsatellite analysis with densitometric profiles. Cases used to define commonly deleted regions (CDRs) are shown. B, blood; 
T, tumour. The bands from tumour templates which showed a decrease of signal intensity compared to blood are indicated by an arrowin blood were very close, but it was clear from the densitometric
profile that the larger allele was missing in the tumour sample (Figure
2). This region is included in some other small deleted regions in
GB33, GB246 and AA86 (Figure 1). Thirty-five tumours (26
glioblastomas and nine anaplastic astrocytomas) showed loss in the
CDR1 region.
GB8 had partial allelic loss at D6S1657 and retained both alleles
at  D6S1563 and  D6S407 (Figures 1 and 2). This case defined
CDR2, a region of 13.1 cM in size. GB33, GB246, GB29, GB229
and GB45 also had small deletions that include CDR2 (Figure 1).
Deleted regions in 39 tumours (29 glioblastomas, nine anaplastic
astrocytomas and one astrocytoma) included CDR2.
GB86, GB145 and AA57 showed an interstitial deletion 
(CDR3, 17 cM) at D6S311, flanked by retention at D6S292 and
D6S441 (Figures 1 and 2). The CDR3 is limited to a 17 cM region by
these cases. GB8, AA105 and A6 also had small deletions including
CDR3 (Figure 1). Regions with allelic loss in 43 tumours (30
glioblastomas, 11 anaplastic astrocytomas and two astrocytomas)
included CDR3.
CDR4 is a 7 cM region between D6S441 and D6S437. The
centromeric border of this region is defined by GB45 which had
retention of both alleles at D6S441 and allelic loss at D6S415
(Figure 1). Allelic loss at D6S415 (GB55) and D6S1577 (GB140)
with retention of both alleles at D6S437 defined the telomeric
border (Figure 1, 2). Deleted regions in 38 tumours (29 glio-
blastomas, eight anaplastic astrocytomas and one astrocytoma)
involved CDR4.
The most telomeric region (CDR5) lies between D6S1599 and
D6S297. The centromeric border for this 11.6 cM region is defined
by AA65 which retained both alleles at D6S1599 and had partial
allelic loss at D6S1719 (Figures 1 and 2). The telomeric border
was defined by AA90 which had partial allelic loss at D6S305 and
retention of both alleles at D6S297 (Figures 1 and 2). The CDR5
was included in the small deletions in GB8, GB29, GB251 and
AA104 (Figure 1). Deletions in 36 tumours (28 glioblastomas,
seven anaplastic astrocytomas and one astrocytoma) involved
CDR5. CDR4 and CDR5 were also included in other larger dele-
tions in GB56, GB38, GB63 and AA86 (Figure 1).
There are six cases which had partial deletions on 6p. Terminal
deletions were observed in GB29, AA90 and A40, and interstitial
deletions in GB44, GB12 and AA7 (Figure 1). Because of the
small number of tumours with deletions, no commonly deleted
region was defined.
For the cases with any deletion, partial and complete allelic
losses are tabulated (Table 2). Partial loss occurred in two out of
two astrocytoma grade II, 11 of 15 (73%) anaplastic astrocytomas
and 22 of 39 (56%) glioblastomas.
When the patterns of partial and complete allelic loss are tabu-
lated (Table 2), it appears that partial loss indicating subpopula-
tions of tumour cells within the tumour occur mainly in
astrocytomas malignancy grade II (no complete losses found) and
anaplastic astrocytomas (the majority (73%) with deletions
showed some degree of partial deletion), while 44% of the
glioblastomas showed complete losses.
When the overall incidence of loss of alleles along the chromo-
some is calculated using the rules defined above for the assessment
of the size of deletions, we find higher frequencies of loss at the
CDRs with a decreased frequencies at 6qter (Figure 4).
The allelic status of chromosome 6 was compared between
primary and recurrent tumours. No significant difference was
observed.
The tumours used in this study have also been examined for
abnormalities of the following tumour suppressor genes and onco-
genes:  CDKN2A/p16INK4A,  CDKN2B/p15INK4B,  CDK4,  MDM2,
RB1, TP53, EGFR and PTEN/MMAC1 (Ichimura et al, 1996; Liu
et al, 1998; Schmidt et al, 1994, 1997, 1999; Ichimura et al, 1999.
No significant correlation between chromosome 6 deletion and
abnormalities of these genes was identified.
DISCUSSION
Thirty-three per cent of the cases in our series showed allelic loss
at one or more loci on 6q. The incidence is higher than that
reported in studies where a smaller number of markers was used
Chromosome 6 deletions in astrocytic tumours 547
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Figure 3 The same tumour DNA template from GB47 showing partial allelic
loss at one locus (D6S275) and complete allelic loss at an adjacent locus
(D6S434). Note the densitometric curve demonstrating partial allelic loss at
D6S275 with approximately 60% decrease of one band and complete allelic
loss at D6S434 with minimum residual signal. The tumour cell content of this
case was 90% (see Figure 1)
Figure 4 Incidence of allelic loss at each locus (see text). Defined
commonly deleted regions (CDRs) are indicated by horizontal bars. cen:
centromere(Fults et al, 1990; Ransom et al, 1992; Liang et al, 1994). The
frequency of allelic loss on 6q was similar in glioblastomas (35%)
and anaplastic astrocytomas (36%) but much lower in astro-
cytomas (14%). The observation that the higher malignancy grade
tumours showed a higher frequency of allelic loss indicates that a
tumour suppressor gene(s) on 6q may play an important role in
malignant progression.
We distinguished partial and complete allelic loss. A pattern
suggesting partial allelic loss may be observed for several reasons.
These include a high percentage of normal cells in the tumour
tissue, PCR artefact, allelic gain or the presence of subpopulations
in the tumour piece. In this study, only tumour pieces with a high
tumour cell content were selected for analysis. For example, GB47
had almost complete loss of one allele at D6S434, which indicated
a minimal amount of normal cells in the tumour piece. Therefore
the high residual signal at D6S275 was not attributed to normal
cells (Figure 3). PCR artefact is unlikely because the extent of
signal reduction was reproducible and generally consistent at
neighbouring loci. Allelic gain is difficult to distinguish from
partial allelic loss by microsatellite analysis alone (Liu et al,
1998). However, it is considered unlikely as CGH studies indicate
that abnormalities of chromosome 6 are almost always deletions
(Mohapatra et al, 1995; Weber et al, 1996). For these reasons we
favour the last possibility – the presence of subpopulations/clones
of tumour cells with different allelic status. When a deletion gives
a growth/survival advantage, the clone will expand, becoming
dominant. The observed partial allelic loss may be a phenomenon
which represents this transition. Among cases with allelic loss 2/2
astrocytomas and 11/15 (73%) anaplastic astrocytomas showed
evidence of partial allelic loss. The incidence was lower in the
glioblastomas; 56% (22/39) of cases with allelic loss have partial
allelic loss (Table 2). All these observations support the idea that
deletion of tumour suppressor gene(s) on 6q plays an important
role in glioma progression.
We have defined five commonly deleted regions. These regions
were deduced under the principle described in the Results section.
The markers which defined all small deleted regions have been
confirmed by at least two independent experiments. The inci-
dences of deletions were relatively similar in CDR2–5 and when
graphed, show peaks as compared to adjacent loci (Figure 4). It is
also notable that the incidence of allele losses decreased at 6qter
arguing against a simple loss of the terminal part of the 6q arm.
Some candidate tumour suppressor genes identified in other
tumours fall into the CDRs determined in our study. The Histone
deacetylase 2 gene (HDAC2) was recently mapped to 6q21 (Betz
et al, 1998) between D6S1563 and D6S1657, the CDR2 region.
HDACs are considered tumour suppressor gene candidates as they
may suppress transcription by modulating chromatin structure.
The oestrogen receptor gene ESR is located between D6S311 and
D6S441, the region included in CDR3. While the involvement of
ESR in gliomas is difficult to support theoretically, its mutation has
been reported in a human breast cancer cell line
(Ponglikitmongkol et al, 1988). The LOT-1 (Lost on transforma-
tion 1) gene also falls into CDR3 and frequent loss of one copy has
been observed in ovarian cancer (Abdollahi et al, 1997). The
protein product of LOT-1 contains zinc finger motifs and is
believed to act as a transcription factor. Two candidate senescence
genes have been mapped to 6q in the CDR1 and CDR5 regions;
SEN 6A (Sandhu et al, 1996) between D6S460 and D6S434
(CDR1) and SEN6 (Banga et al, 1997) between D6S1719 and
D6S281 (CDR5). In glioma, no candidate tumour suppressor
genes have ever been proposed on chromosome 6.
Even though some of the CDRs are represented by single
markers, the regions defined by our study span large genomic
regions. Further narrowing down of the minimum region of
deletion is necessary to facilitate focusing on candidate genes to
investigate their relevancy as tumour suppressor genes. The ever
increasing chromosome and gene data being produced, together
with the efforts to localize candidate regions as presented here,
facilitate the identification of novel tumour suppressor genes.
While it might seem unlikely that all five CDRs represent truly
interesting areas the findings here clearly warrant further investi-
gation.
In conclusion, we have confirmed the high frequency of dele-
tion of the long arm of chromosome 6 in malignant astrocytic
tumours and have defined a number of critical regions. Clonal
heterogeneity was observed but found to diminish in the most
malignant tumour group, the glioblastomas. The evidence suggests
that the long arm of chromosome 6 harbours tumour suppressor
genes which may be involved in malignant progression of astro-
cytic gliomas.
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